## Carlos Cordon-Cardo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7592171/publications.pdf

Version: 2024-02-01

371 papers

63,951 citations

117 h-index 243 g-index

390 all docs

390 docs citations

times ranked

390

78065 citing authors

#	Article	IF	CITATIONS
1	A microRNA polycistron as a potential human oncogene. Nature, 2005, 435, 828-833.	13.7	3,390
2	A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 2003, 3, 537-549.	7.7	2,325
3	Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature, 2007, 445, 656-660.	13.7	2,159
4	An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature Medicine, 2020, 26, 1636-1643.	15.2	1,860
5	Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature, 2005, 436, 725-730.	13.7	1,768
6	Role of the INK4a Locus in Tumor Suppression and Cell Mortality. Cell, 1996, 85, 27-37.	13.5	1,512
7	Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis. Science, 2003, 300, 1155-1159.	6.0	1,474
8	Pten is essential for embryonic development and tumour suppression. Nature Genetics, 1998, 19, 348-355.	9.4	1,428
9	The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53. Cell, 1998, 92, 713-723.	13.5	1,412
10	Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice. Science, 2001, 293, 293-297.	6.0	1,194
11	Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science, 2020, 370, 1227-1230.	6.0	1,035
12	Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach. Cell, 2006, 125, 1253-1267.	13.5	989
13	Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature, 2001, 409, 207-211.	13.7	901
14	Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature, 2004, 428, 332-337.	13.7	898
15	The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell, 1991, 66, 395-403.	13.5	881
16	Essential role for oncogenic Ras in tumour maintenance. Nature, 1999, 400, 468-472.	13.7	855
17	Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nature Medicine, 2007, 13, 1203-1210.	15.2	804
18	Acid Sphingomyelinase–Deficient Human Lymphoblasts and Mice Are Defective in Radiation-Induced Apoptosis. Cell, 1996, 86, 189-199.	13.5	780

#	Article	IF	CITATIONS
19	Differential exoprotease activities confer tumor-specific serum peptidome patterns. Journal of Clinical Investigation, 2005, 116, 271-284.	3.9	683
20	Ubiquitination Regulates PTEN Nuclear Import and Tumor Suppression. Cell, 2007, 128, 141-156.	13.5	652
21	NEDD4-1 Is a Proto-Oncogenic Ubiquitin Ligase for PTEN. Cell, 2007, 128, 129-139.	13.5	630
22	Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nature Genetics, 2009, 41, 619-624.	9.4	595
23	Pten Dose Dictates Cancer Progression in the Prostate. PLoS Biology, 2003, 1, e59.	2.6	593
24	Mad2 Overexpression Promotes Aneuploidy and Tumorigenesis in Mice. Cancer Cell, 2007, 11, 9-23.	7.7	556
25	<i>miR-19</i> is a key oncogenic component of <i>mir-17-92</i> . Genes and Development, 2009, 23, 2839-2849.	2.7	540
26	The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nature Medicine, 2004, 10, 484-486.	15.2	536
27	The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3. Cell, 1991, 66, 173-183.	13.5	521
28	Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature, 2004, 430, 797-802.	13.7	517
29	Defining Molecular Profiles of Poor Outcome in Patients With Invasive Bladder Cancer Using Oligonucleotide Microarrays. Journal of Clinical Oncology, 2006, 24, 778-789.	0.8	513
30	AKI in Hospitalized Patients with COVID-19. Journal of the American Society of Nephrology: JASN, 2021, 32, 151-160.	3.0	500
31	Impaired Fas Response and Autoimmunity in Pten+/ Mice. Science, 1999, 285, 2122-2125.	6.0	490
32	Role of PML in Cell Growth and the Retinoic Acid Pathway. Science, 1998, 279, 1547-1551.	6.0	488
33	Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature, 2005, 433, 278-285.	13.7	461
34	Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nature Genetics, 2001, 27, 222-224.	9.4	458
35	SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respiratory Medicine, the, 2020, 8, e70.	5.2	432
36	Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature, 2005, 436, 807-811.	13.7	419

#	Article	IF	CITATIONS
37	$\hat{I}^3$ -secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nature Medicine, 2009, 15, 50-58.	15.2	417
38	Lipopolysaccharide Induces Disseminated Endothelial Apoptosis Requiring Ceramide Generation. Journal of Experimental Medicine, 1997, 186, 1831-1841.	4.2	412
39	Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study. Nature Medicine, 2020, 26, 1708-1713.	15.2	405
40	Dyskeratosis Congenita and Cancer in Mice Deficient in Ribosomal RNA Modification. Science, 2003, 299, 259-262.	6.0	387
41	Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. Journal of the American College of Cardiology, 2020, 76, 1815-1826.	1.2	383
42	Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene. Cell, 2006, 125, 1269-1281.	13.5	380
43	p63 expression profiles in human normal and tumor tissues. Clinical Cancer Research, 2002, 8, 494-501.	3.2	378
44	Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells. Cancer Cell, 2012, 22, 373-388.	7.7	368
45	Validation of Tissue Microarrays for Immunohistochemical Profiling of Cancer Specimens Using the Example of Human Fibroblastic Tumors. American Journal of Pathology, 2001, 158, 1245-1251.	1.9	362
46	Identification of a tumour suppressor network opposing nuclear Akt function. Nature, 2006, 441, 523-527.	13.7	362
47	Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature, 2010, 464, 374-379.	13.7	357
48	17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clinical Cancer Research, 2002, 8, 986-93.	3.2	357
49	PML inhibits HIF- $1\hat{l}_{\pm}$ translation and neoangiogenesis through repression of mTOR. Nature, 2006, 442, 779-785.	13.7	354
50	A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nature Medicine, 2014, 20, 1130-1137.	15.2	349
51	An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nature Genetics, 2003, 33, 396-400.	9.4	342
52	Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. Journal of Clinical Investigation, 2008, 118, 3051-64.	3.9	319
53	HIV antigen in the brains of patients with the AIDS dementia complex. Annals of Neurology, 1987, 21, 490-496.	2.8	308
54	Autocrine PDGFR signaling promotes mammary cancer metastasis. Journal of Clinical Investigation, 2006, 116, 1561-1570.	3.9	307

#	Article	IF	Citations
55	Loss of the Tumor Suppressor PML in Human Cancers of Multiple Histologic Origins. Journal of the National Cancer Institute, 2004, 96, 269-279.	3.0	304
56	PHF6 mutations in T-cell acute lymphoblastic leukemia. Nature Genetics, 2010, 42, 338-342.	9.4	282
57	The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nature Medicine, 2007, 13, 748-753.	15.2	275
58	Inactivation of <i>p53</i> and <i>Pten</i> promotes invasive bladder cancer. Genes and Development, 2009, 23, 675-680.	2.7	268
59	Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides., 1997, 73, 42-49.		254
60	Ku70 Is Required for DNA Repair but Not for T Cell Antigen Receptor Gene Recombination In Vivo. Journal of Experimental Medicine, 1997, 186, 921-929.	4.2	249
61	High-resolution characterization of the pancreatic adenocarcinoma genome. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9067-9072.	3.3	246
62	Tissue Microarray Profiling of Cancer Specimens and Cell Lines: Opportunities and Limitations. Laboratory Investigation, 2001, 81, 1331-1338.	1.7	245
63	Declining p53 function in the aging process: A possible mechanism for the increased tumor incidence in older populations. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16633-16638.	3.3	243
64	Association of the Lewis Blood-Group Phenotype with Recurrent Urinary Tract Infections in Women. New England Journal of Medicine, 1989, 320, 773-777.	13.9	240
65	Loss of p63 Expression Is Associated with Tumor Progression in Bladder Cancer. American Journal of Pathology, 2002, 161, 1199-1206.	1.9	240
66	Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nature Communications, 2015, 6, 6087.	5.8	240
67	An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nature Genetics, 2018, 50, 206-218.	9.4	229
68	Molecular pathways of urothelial development and bladder tumorigenesis. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 401-408.	0.8	228
69	exRNA Atlas Analysis Reveals Distinct Extracellular RNA Cargo Types and Their Carriers Present across Human Biofluids. Cell, 2019, 177, 463-477.e15.	13.5	228
70	EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nature Communications, 2018, 9, 3503.	5.8	224
71	p53 mutations in human bladder cancer: Genotypicversus phenotypic patterns. International Journal of Cancer, 1994, 56, 347-353.	2.3	220
72	Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia. Cancer Cell, 2013, 24, 766-776.	7.7	220

#	Article	IF	CITATIONS
73	Ku70. Molecular Cell, 1998, 2, 1-8.	4.5	217
74	Altered Expression of the Retinoblastoma Gene Product in Human Sarcomas. New England Journal of Medicine, 1990, 323, 1457-1462.	13.9	212
75	Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens., 1997, 73, 50-56.		212
76	Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Research, 2003, 63, 2872-80.	0.4	208
77	Classification and Subtype Prediction of Adult Soft Tissue Sarcoma by Functional Genomics. American Journal of Pathology, 2003, 163, 691-700.	1.9	207
78	Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent Mechanism. Clinical Cancer Research, 2005, $11$ , $1999-2007$ .	3.2	194
79	Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature, 1998, 393, 483-487.	13.7	190
80	MDM2 and Prognosis. Molecular Cancer Research, 2004, 2, 1-8.	1.5	189
81	Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Modern Pathology, 2021, 34, 1456-1467.	2.9	184
82	PTEN counteracts FBXL2 to promote IP3R3- and Ca2+-mediated apoptosis limiting tumour growth. Nature, 2017, 546, 554-558.	13.7	182
83	Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nature Medicine, 2015, 21, 1182-1189.	15.2	180
84	Gene Discovery in Bladder Cancer Progression using cDNA Microarrays. American Journal of Pathology, 2003, 163, 505-516.	1.9	177
85	Classification of Clear-Cell Sarcoma as a Subtype of Melanoma by Genomic Profiling. Journal of Clinical Oncology, 2003, 21, 1775-1781.	0.8	177
86	The metabolic co-regulator PGC1α suppresses prostate cancer metastasis. Nature Cell Biology, 2016, 18, 645-656.	4.6	176
87	Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell, 2021, 39, 1028-1030.	7.7	176
88	Machine Learning to Predict Mortality and Critical Events in a Cohort of Patients With COVID-19 in New York City: Model Development and Validation. Journal of Medical Internet Research, 2020, 22, e24018.	2.1	174
89	The ETS Protein MEF Plays a Critical Role in Perforin Gene Expression and the Development of Natural Killer and NK-T Cells. Immunity, 2002, 17, 437-449.	6.6	173
90	Tissue-specific and reversible RNA interference in transgenic mice. Nature Genetics, 2007, 39, 914-921.	9.4	170

#	Article	IF	Citations
91	<i>DLC1</i> is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes and Development, 2008, 22, 1439-1444.	2.7	167
92	Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. Journal of Clinical Investigation, 2007, $117$ , $3248$ - $3257$ .	3.9	167
93	Integrative Genome Comparison of Primary and Metastatic Melanomas. PLoS ONE, 2010, 5, e10770.	1.1	166
94	Bladder cancers arise from distinct urothelial sub-populations. Nature Cell Biology, 2014, 16, 982-991.	4.6	163
95	Profiling Bladder Cancer Using Targeted Antibody Arrays. American Journal of Pathology, 2006, 168, 93-103.	1.9	162
96	Deletions of the INK4A Gene Occur in Malignant Peripheral Nerve Sheath Tumors but not in Neurofibromas. American Journal of Pathology, 1999, 155, 1855-1860.	1.9	161
97	Gli Activity Correlates with Tumor Grade in Platelet-Derived Growth Factor–Induced Gliomas. Cancer Research, 2008, 68, 2241-2249.	0.4	160
98	Identification of PHLPP1 as a Tumor Suppressor Reveals the Role of Feedback Activation in PTEN-Mutant Prostate Cancer Progression. Cancer Cell, 2011, 20, 173-186.	7.7	158
99	Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Research, 2003, 63, 7799-806.	0.4	158
100	Role of the chromobox protein CBX7 in lymphomagenesis. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5389-5394.	3.3	150
101	Tumor Suppressor Role of KiSS-1 in Bladder Cancer. American Journal of Pathology, 2003, 162, 609-617.	1.9	148
102	p27 as a target for cancer therapeutics. Cancer Cell, 2003, 3, 111-115.	7.7	146
103	Role of Promyelocytic Leukemia (Pml) Protein in Tumor Suppression. Journal of Experimental Medicine, 2001, 193, 521-530.	4.2	145
104	Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Research, 2002, 62, 6973-80.	0.4	144
105	miR-143, miR-222, and miR-452 Are Useful as Tumor Stratification and Noninvasive Diagnostic Biomarkers for Bladder Cancer. American Journal of Pathology, 2012, 180, 1808-1815.	1.9	142
106	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature, 2017, 547, 109-113.	13.7	142
107	Overexpression of Phospho-elF4E Is Associated with Survival through AKT Pathway in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2010, 16, 240-248.	3.2	141
108	The TLX1 oncogene drives aneuploidy in T cell transformation. Nature Medicine, 2010, 16, 1321-1327.	15.2	139

#	Article	IF	CITATIONS
109	A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nature Genetics, 2013, 45, 747-755.	9.4	138
110	Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nature Genetics, 2013, 45, 739-746.	9.4	134
111	Clinical and Pathobiological Effects of Neoadjuvant Total Androgen Ablation Therapy on Clinically Localized Prostatic Adenocarcinoma. American Journal of Surgical Pathology, 1994, 18, 979-991.	2.1	133
112	Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes and Cancer, 2006, 45, 447-454.	1.5	133
113	Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. Lancet Microbe, The, 2020, 1, e283-e289.	3.4	133
114	Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clinical Cancer Research, 2002, 8, 679-83.	3.2	132
115	Integrated nanoscale deterministic lateral displacement arrays for separation of extracellular vesicles from clinically-relevant volumes of biological samples. Lab on A Chip, 2018, 18, 3913-3925.	3.1	129
116	Identification of S664 TSC2 Phosphorylation as a Marker for Extracellular Signal-Regulated Kinase–Mediated mTOR Activation in Tuberous Sclerosis and Human Cancer. Cancer Research, 2007, 67, 7106-7112.	0.4	128
117	A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer. Cancer Cell, 2015, 27, 223-239.	7.7	128
118	3-Phosphoinositide–Dependent Kinase 1 Potentiates Upstream Lesions on the Phosphatidylinositol 3-Kinase Pathway in Breast Carcinoma. Cancer Research, 2009, 69, 6299-6306.	0.4	126
119	MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century. Expert Review of Anticancer Therapy, 2009, 9, 1135-1144.	1.1	126
120	At the Crossroads of Inflammation and Tumorigenesis. Journal of Experimental Medicine, 1999, 190, 1367-1370.	4.2	125
121	Deletions of the INK4A Gene in Superficial Bladder Tumors. American Journal of Pathology, 1999, 155, 105-113.	1.9	121
122	Intragenic antagonistic roles of protein and circRNA in tumorigenesis. Cell Research, 2019, 29, 628-640.	5.7	121
123	Expression of p27kip and Other Cell Cycle Regulators in Malignant Peripheral Nerve Sheath Tumors and Neurofibromas. American Journal of Pathology, 1999, 155, 1885-1891.	1.9	120
124	Alveolar rhabdomyosarcoma: Is the cell of origin a mesenchymal stem cell?. Cancer Letters, 2009, 279, 126-136.	3.2	119
125	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. Gastroenterology, 2021, 160, 2435-2450.e34.	0.6	118
126	Mzf1 controls cell proliferation and tumorigenesis. Genes and Development, 2001, 15, 1625-1630.	2.7	117

#	Article	IF	CITATIONS
127	Distinct Expression Profiles of p63 Variants during Urothelial Development and Bladder Cancer Progression. American Journal of Pathology, 2011, 178, 1350-1360.	1.9	114
128	The Precrystalline Cytoplasmic Granules of Alveolar Soft Part Sarcoma Contain Monocarboxylate Transporter 1 and CD147. American Journal of Pathology, 2002, 160, 1215-1221.	1.9	109
129	A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol. Clinical Cancer Research, 2005, 11, 3836-3845.	3.2	109
130	Aberrant <i>Rheb</i> -mediated mTORC1 activation and <i>Pten</i> haploinsufficiency are cooperative oncogenic events. Genes and Development, 2008, 22, 2172-2177.	2.7	109
131	Oncogenes in melanoma. Oncogene, 2003, 22, 3087-3091.	2.6	107
132	Preclinical Analysis of the $\hat{I}^3$ -Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia. Molecular Cancer Therapeutics, 2012, 11, 1565-1575.	1.9	104
133	Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clinical Cancer Research, 2002, 8, 171-9.	3.2	104
134	Improved prediction of prostate cancer recurrence through systems pathology. Journal of Clinical Investigation, 2007, 117, 1876-1883.	3.9	102
135	Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes and Development, 2005, 19, 1779-1786.	2.7	101
136	Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. Journal of Clinical Investigation, 2007, 117, 314-325.	3.9	101
137	Evaluation of the Performance of a p53 Sequencing Microarray Chip Using 140 Previously Sequenced Bladder Tumor Samples. Clinical Chemistry, 2000, 46, 1555-1561.	1.5	99
138	TREK-1 Is a Novel Molecular Target in Prostate Cancer. Cancer Research, 2008, 68, 1197-1203.	0.4	99
139	Translocation Renal Cell Carcinomas in Adults. American Journal of Surgical Pathology, 2012, 36, 654-662.	2.1	98
140	Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer, 1992, 70, 633-638.	2.0	97
141	Comparison of SARSâ€CoVâ€2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARSâ€CoVâ€2 test and a laboratoryâ€developed realâ€time RTâ€PCR test. Journal of Medical Virology, 2020, 92, 1695-1698.	, 2.5	97
142	Adrenocortical Adenoma and Carcinoma: Histopathological and Molecular Comparative Analysis. Modern Pathology, 2003, 16, 742-751.	2.9	96
143	Determinants of Sensitivity and Resistance to Rapamycin-Chemotherapy Drug Combinations In vivo. Cancer Research, 2006, 66, 7639-7646.	0.4	96
144	Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR <sup>â^²</sup> /HER2 <sup>+</sup> breast cancers. Genes and Development, 2015, 29, 1631-1648.	2.7	94

#	Article	IF	CITATIONS
145	Molecular analyses of the mitotic checkpoint componentshsMAD2, hBUB1 andhBUB3 in human cancer. International Journal of Cancer, 2001, 95, 223-227.	2.3	92
146	Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma., 1998, 83, 490-497.		90
147	Expression of Transforming Growth Factor-α and the Epidermal Growth Factor Receptor in Human Prostate Tissues. Journal of Urology, 1994, 152, 2120-2124.	0.2	89
148	High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer, 2001, 92, 869-874.	2.0	89
149	FBXW7 Mutations in Melanoma and a New Therapeutic Paradigm. Journal of the National Cancer Institute, 2014, 106, dju107.	3.0	87
150	miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes and Development, 2017, 31, 553-566.	2.7	87
151	Amplification of the 3q26.3 Locus Is Associated with Progression to Invasive Cancer and Is a Negative Prognostic Factor in Head and Neck Squamous Cell Carcinomas. American Journal of Pathology, 2002, 161, 365-371.	1.9	86
152	Systems Pathology Approach for the Prediction of Prostate Cancer Progression After Radical Prostatectomy. Journal of Clinical Oncology, 2008, 26, 3923-3929.	0.8	85
153	Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clinical Cancer Research, 2002, 8, 3226-31.	3.2	85
154	Alterations of Cell Cycle Regulators in Localized Synovial Sarcoma. American Journal of Pathology, 2000, 156, 977-983.	1.9	84
155	Targeting Nonclassical Oncogenes for Therapy in T-ALL. Cancer Cell, 2012, 21, 459-472.	7.7	84
156	RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of <i>Pten</i> -Mutant Metastasis. Cancer Discovery, 2014, 4, 318-333.	7.7	83
157	Role of Dok-1 and Dok-2 in Leukemia Suppression. Journal of Experimental Medicine, 2004, 200, 1689-1695.	4.2	82
158	Clinical Significance of Molecular Expression Profiles of Hýrthle Cell Tumors of the Thyroid Gland Analyzed via Tissue Microarrays. American Journal of Pathology, 2002, 160, 175-183.	1.9	79
159	Artificial intelligence in neuropathology: deep learning-based assessment of tauopathy. Laboratory Investigation, 2019, 99, 1019-1029.	1.7	79
160	Differentiation Antigens of Melanocytes and Melanoma: Analysis of Melanosome and Cell Surface Markers of Human Pigmented Cells With Monoclonal Antibodies. Journal of Investigative Dermatology, 1988, 90, 459-466.	0.3	78
161	Cyfip1 Is a Putative Invasion Suppressor in Epithelial Cancers. Cell, 2009, 137, 1047-1061.	13.5	77
162	Thymidylate Synthase Expression in Hepatic Tumors Is a Predictor of Survival and Progression in Patients With Resectable Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2003, 21, 406-412.	0.8	76

#	Article	IF	Citations
163	Association of Nuclear Localization of a Long Interspersed Nuclear Element-1 Protein in Breast Tumors with Poor Prognostic Outcomes. Genes and Cancer, 2010, 1, 115-124.	0.6	76
164	Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder Cancer. Cancer Prevention Research, 2009, 2, 1008-1014.	0.7	75
165	HDM2 Protein Overexpression and Prognosis in Primary Malignant Melanoma. Journal of the National Cancer Institute, 2002, 94, 1803-1806.	3.0	74
166	Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation. Nature Genetics, 2004, 36, 906-912.	9.4	74
167	p73α Regulation by Chk1 in Response to DNA Damage. Molecular and Cellular Biology, 2003, 23, 8161-8171.	1.1	<b>7</b> 3
168	Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3594-3596.e3.	2.0	72
169	The role of GATA2 in lethal prostate cancer aggressiveness. Nature Reviews Urology, 2017, 14, 38-48.	1.9	71
170	Neutralizing Antibody Responses in COVID-19 Convalescent Sera. Journal of Infectious Diseases, 2021, 223, 47-55.	1.9	70
171	Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. European Urology, 2016, 70, 771-775.	0.9	69
172	P-glycoprotein expression in brain tumors. Journal of Neuro-Oncology, 1992, 14, 37-43.	1.4	68
173	The <i>miR-424(322)/503</i> cluster orchestrates remodeling of the epithelium in the involuting mammary gland. Genes and Development, 2014, 28, 765-782.	2.7	66
174	A Developmental Model of Sarcomagenesis Defines a Differentiation-Based Classification for Liposarcomas. American Journal of Pathology, 2008, 172, 1069-1080.	1.9	65
175	Disruption of a <i>Sirt1</i> Ii>-Dependent Autophagy Checkpoint in the Prostate Results in Prostatic Intraepithelial Neoplasia Lesion Formation. Cancer Research, 2011, 71, 964-975.	0.4	65
176	MYC Drives <i>Pten/Trp53</i> Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. Cancer Discovery, 2015, 5, 636-651.	7.7	65
177	Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood, 2004, 103, 2358-2362.	0.6	64
178	Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis. Science Signaling, 2009, 2, ra2.	1.6	64
179	Immunohistologic expression of blood-group antigens in normal human gastrointestinal tract and colonic carcinoma. International Journal of Cancer, 1986, 37, 667-676.	2.3	63
180	Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. Cancer Cell, 2021, 39, 1442-1444.	7.7	62

#	Article	IF	CITATIONS
181	Genetic and Molecular Markers of Urothelial Premalignancy and Malignancy. Scandinavian Journal of Urology and Nephrology, 2000, 34, 82-93.	1.4	61
182	Effect of p27 Deficiency and Rapamycin on Intimal Hyperplasia: In Vivo and In Vitro Studies Using a p27 Knockout Mouse Model. Laboratory Investigation, 2001, 81, 895-903.	1.7	61
183	Alteration of p53 Pathway in Squamous Cell Carcinoma of the Head and Neck: Impact on Treatment Outcome in Patients Treated With Larynx Preservation Intent. Journal of Clinical Oncology, 2002, 20, 2980-2987.	0.8	61
184	Drg1 Expression in 131 Colorectal Liver Metastases: Correlation with Clinical Variables and Patient Outcomes. Clinical Cancer Research, 2005, 11, 3296-3302.	3.2	61
185	Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Research, 2003, 63, 5703-6.	0.4	60
186	Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumor Biology, 2010, 31, 277-285.	0.8	59
187	Androgen receptor expression is associated with prostate cancerâ€specific survival in castrate patients with metastatic disease. BJU International, 2010, 105, 462-467.	1.3	59
188	Molecular Alterations Associated With Bladder Cancer Progression. Seminars in Oncology, 2007, 34, 75-84.	0.8	58
189	Chk2 Suppresses the Oncogenic Potential of DNA Replication-Associated DNA Damage. Molecular Cell, 2008, 31, 21-32.	4.5	58
190	Changes in Cell Surface Glycoprotein Expression During Differentiation of Human Keratinocytes. Journal of Investigative Dermatology, 1987, 89, 500-506.	0.3	57
191	Impact of Stromal Sensitivity on Radiation Response of Tumors Implanted in SCID Hosts Revisited. Cancer Research, 2010, 70, 8179-8186.	0.4	57
192	PPARγ agonists enhance ET-743–induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. Journal of Clinical Investigation, 2012, 122, 886-898.	3.9	56
193	Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. Clinical Cancer Research, 2002, 8, 782-7.	3.2	55
194	Prognostic Significance of Transcription Factor E2F-1 in Bladder Cancer: Genotypic and Phenotypic Characterization. Journal of the National Cancer Institute, 1999, 91, 874-881.	3.0	54
195	A Polymorphism in HDM2 (SNP309) Associates with Early Onset in Superficial Tumors, TP53 Mutations, and Poor Outcome in Invasive Bladder Cancer. Clinical Cancer Research, 2007, 13, 3215-3220.	3.2	54
196	Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Clinical Cancer Research, 2003, 9, 2613-9.	3.2	54
197	Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Molecular Cancer Therapeutics, 2004, 3, 921-32.	1.9	54
198	Gene expression profiling in single cells within tissue. Nature Methods, 2005, 2, 663-665.	9.0	52

#	Article	IF	CITATIONS
199	Personalized Prediction of Tumor Response and Cancer Progression on Prostate Needle Biopsy. Journal of Urology, 2009, 182, 125-132.	0.2	52
200	Loss of Sirt1 Promotes Prostatic Intraepithelial Neoplasia, Reduces Mitophagy, and Delays Park2 Translocation to Mitochondria. American Journal of Pathology, 2015, 185, 266-279.	1.9	51
201	p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. Clinical Cancer Research, 2003, 9, 5642-51.	3.2	51
202	Modulation of apoptosis, proliferation, and p27 expression in a porcine coronary angioplasty model. Atherosclerosis, 2000, 153, 315-322.	0.4	50
203	Somatic cell type specific gene transfer reveals a tumor-promoting function for p21Waf1/Cip1. EMBO Journal, 2007, 26, 4683-4693.	3.5	50
204	Three-Dimensional Culture of Mouse Renal Carcinoma Cells in Agarose Macrobeads Selects for a Subpopulation of Cells with Cancer Stem Cell or Cancer Progenitor Properties. Cancer Research, 2011, 71, 716-724.	0.4	50
205	Retrospective cohort study of clinical characteristics of 2199 hospitalised patients with COVID-19 in New York City. BMJ Open, 2020, 10, e040736.	0.8	50
206	Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury. Journal of Clinical Investigation, 2019, 129, 786-801.	3.9	50
207	Genetic studies and molecular markers of bladder cancer., 1997, 13, 319-327.		49
208	A Role for PML in Innate Immunity. Genes and Cancer, 2011, 2, 10-19.	0.6	49
209	Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. Clinical Cancer Research, 2002, 8, 3841-9.	3.2	49
210	Macrophage-Derived Chemokine Expression in Classical Hodgkin's Lymphoma: Application of Tissue Microarrays. Modern Pathology, 2001, 14, 1270-1276.	2.9	48
211	Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome. Oncogene, 2003, 22, 5298-5305.	2.6	48
212	COVID-19: Staging of a New Disease. Cancer Cell, 2020, 38, 594-597.	7.7	48
213	MUTATION OF CELL CYCLE REGULATORS AND THEIR IMPACT ON SUPERFICIAL BLADDER CANCER. Urologic Clinics of North America, 2000, 27, 83-102.	0.8	47
214	Distribution of the ganglioside GD3 in the human nervous system detected by R24 mouse monoclonal antibody. Brain Research, 1984, 324, 190-194.	1.1	45
215	Expression of Granulocyte-Macrophage Colony-Stimulating Factor Receptors in Human Prostate Cancer. Blood, 1998, 91, 1037-1043.	0.6	44
216	KISS1 Methylation and Expression as Tumor Stratification Biomarkers and Clinical Outcome Prognosticators for Bladder Cancer Patients. American Journal of Pathology, 2011, 179, 540-546.	1.9	44

#	Article	IF	CITATIONS
217	Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy $\hat{a} \in \mathbb{C}$ Achieving global consensus and visibility for cellular host-directed therapies. International Journal of Infectious Diseases, 2020, 96, 431-439.	1.5	43
218	Characterization of Desmoglein Expression in the Normal Prostatic Gland. Desmoglein 2 Is an Independent Prognostic Factor for Aggressive Prostate Cancer. PLoS ONE, 2014, 9, e98786.	1.1	43
219	Cell surface antigens of human trophoblast and choriocarcinoma defined by monoclonal antibodies. International Journal of Cancer, 1985, 35, 469-475.	2.3	42
220	Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. Journal of Visualized Experiments, 2015, , 53182.	0.2	40
221	Bcl-2 and Bax expression in thyroid tumours An immunohistochemical and Western blot analysis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1997, 430, 125-130.	1.4	39
222	p73Î <sup>2</sup> -Mediated Apoptosis Requires p57kip2 Induction and IEX-1 Inhibition. Cancer Research, 2005, 65, 2186-2192.	0.4	39
223	The MicroRNA 424/503 Cluster Reduces CDC25A Expression during Cell Cycle Arrest Imposed by Transforming Growth Factor $\hat{l}^2$ in Mammary Epithelial Cells. Molecular and Cellular Biology, 2014, 34, 4216-4231.	1.1	39
224	Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target. Oncoscience, 2015, 2, 607-614.	0.9	38
225	Identification of PMF1 Methylation in Association with Bladder Cancer Progression. Clinical Cancer Research, 2008, 14, 8236-8243.	3.2	37
226	<scp>PI</scp> 3K/ <scp>AKT</scp> pathway regulates E adherin and Desmoglein 2 in aggressive prostate cancer. Cancer Medicine, 2015, 4, 1258-1271.	1.3	37
227	Genetic and Immunophenotype Analyses of TP53 in Bladder Cancer. Diagnostic Molecular Pathology, 2004, 13, 217-223.	2.1	36
228	Single nucleotide polymorphisms of 8 inflammationâ€related genes and their associations with smokingâ€related cancers. International Journal of Cancer, 2010, 127, 2169-2182.	2.3	36
229	Associations between NBS1 polymorphisms, haplotypes and smoking-related cancers. Carcinogenesis, 2010, 31, 1264-1271.	1.3	36
230	Biomarkers for bladder cancer management: present and future. American Journal of Clinical and Experimental Urology, 2014, 2, 1-14.	0.4	36
231	The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein. Journal of Cell Biology, 2017, 216, 641-656.	2.3	35
232	Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer., 1996, 69, 110-113.		34
233	Prediction of Prostate Cancer Recurrence Using Magnetic Resonance Imaging and Molecular Profiles. Clinical Cancer Research, 2009, 15, 3842-3849.	3.2	34
234	A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2â€T4aN0â€N2M0 bladder cancer. Cancer, 2012, 118, 358-364.	2.0	34

#	Article	IF	CITATIONS
235	Technology Insight: will systems pathology replace the pathologist?. Nature Reviews Urology, 2007, 4, 39-45.	1.4	33
236	Prognostic significance of p27Kip1expression in bladder cancer. BJU International, 2007, 100, 259-263.	1.3	33
237	Broad Severe Acute Respiratory Syndrome Coronavirus 2 Cell Tropism and Immunopathology in Lung Tissues From Fatal Coronavirus Disease 2019. Journal of Infectious Diseases, 2021, 223, 1842-1854.	1.9	33
238	Inhibition of Orthotopic Human Bladder Tumor Growth by Lentiviral Gene Transfer of Endostatin. Clinical Cancer Research, 2004, 10, 1835-1842.	3.2	32
239	Tissue-based SARS-CoV-2 detection in fatal COVID-19 infections: Sustained direct viral-induced damage is not necessary to drive disease progression. Human Pathology, 2021, 114, 110-119.	1.1	32
240	Genotypic and phenotypic characterization of the histoblood group ABO(H) in primary bladder tumors., 1998, 75, 819-824.		31
241	Genomic and Proteomic Profiles Reveal the Association of Gelsolin to TP53 Status and Bladder Cancer Progression. American Journal of Pathology, 2007, 171, 1650-1658.	1.9	30
242	Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder. Cancer Research, 2003, 63, 179-85.	0.4	30
243	Relation between human papillomavirus positivity and p16 expression in head and neck carcinomas-a tissue microarray study. Anticancer Research, 2007, 27, 283-8.	0.5	30
244	Highly Efficient Gene Delivery for Bladder Cancers by Intravesically Administered Replication-Competent Retroviral Vectors. Clinical Cancer Research, 2007, 13, 4511-4518.	3.2	29
245	p53 is localized to a sub-nucleolar compartment after proteasomal inhibition in an energy-dependent manner. Journal of Cell Science, 2008, 121, 4098-4105.	1.2	29
246	Correlation of MR Imaging and MR Spectroscopic Imaging Findings with Ki-67, Phospho-Akt, and Androgen Receptor Expression in Prostate Cancer. Radiology, 2009, 250, 803-812.	3.6	29
247	Reappraising hyalinizing clear cell carcinoma: A populationâ€based study with molecular confirmation. Head and Neck, 2017, 39, 503-511.	0.9	29
248	RTâ€PCR/MALDIâ€TOF mass spectrometryâ€based detection of SARSâ€CoVâ€2 in saliva specimens. Journal of Medical Virology, 2021, 93, 5481-5486.	2.5	29
249	DNA Microchips: Technical and Practical Considerations. Current Organic Chemistry, 2000, 4, 945-971.	0.9	29
250	Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients. Cancer Cell, 2022, 40, 441-443.	7.7	29
251	Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling. American Journal of Pathology, 2016, 186, 3131-3145.	1.9	28
252	p27 deficiency desensitizes Rbâ^'/â^' cells to signals that trigger apoptosis during pituitary tumor development. Oncogene, 2003, 22, 361-369.	2.6	27

#	Article	IF	CITATIONS
253	A Common MicroRNA Signature Consisting of miR-133a, miR-139-3p, and miR-142-3p Clusters Bladder Carcinoma in Situ with Normal Umbrella Cells. American Journal of Pathology, 2013, 182, 1171-1179.	1.9	26
254	Expression Profiling of Osteosarcoma Cells Transfected with MDR1 and NEO Genes: Regulation of Cell Adhesion, Apoptosis, and Tumor Suppression-Related Genes. Laboratory Investigation, 2003, 83, 507-517.	1.7	25
255	Apoptosis, proliferation, and p27 expression during vessel wall healing: Time course study in a mouse model of transluminal femoral artery injury. Journal of Vascular Surgery, 2000, 32, 1022-1029.	0.6	24
256	Suppression of <i>CHK1</i> by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. Cancer Discovery, 2015, 5, 550-563.	7.7	24
257	Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. Gut, 2022, 71, 2069-2080.	6.1	24
258	Genetic Alterations of the p14ARF-hdm2-p53 Regulatory Pathway in Breast Carcinoma. Breast Cancer Research and Treatment, 2001, 65, 225-232.	1.1	23
259	Analysis of sex-specific risk factors and clinical outcomes in COVID-19. Communications Medicine, $2021, 1, \dots$	1.9	23
260	Chromosome 16 in primary prostate cancer: A microsatellite analysis., 1997, 71, 580-584.		22
261	A Genetic Platform to Model Sarcomagenesis from Primary Adult Mesenchymal Stem Cells. Cancer Discovery, 2015, 5, 396-409.	7.7	22
262	Development and validation of a novel automated Gleason grade and molecular profile that define a highly predictive prostate cancer progression algorithm-based test. Prostate Cancer and Prostatic Diseases, 2018, 21, 594-603.	2.0	22
263	A context dependent role for Wnt signaling in tumorigenesis and stem cells. Cell Cycle, 2008, 7, 720-724.	1.3	21
264	Systems pathology. Cancer, 2009, 115, 3078-3084.	2.0	21
265	Dual Pten/Tp53 Suppression Promotes Sarcoma Progression by Activating Notch Signaling. American Journal of Pathology, 2013, 182, 2015-2027.	1.9	21
266	Î"Np63 Expression is a Protective Factor of Progression in Clinical High Grade T1 Bladder Cancer. Journal of Urology, 2015, 193, 1144-1150.	0.2	21
267	Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 419-426.	2.2	20
268	Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. Oncogene, 2018, 37, 5858-5872.	2.6	20
269	Tissue Distribution of GD3 Ganglioside Detected by Mouse Monoclonal Antibody R24. American Journal of Dermatopathology, 1989, 11, 577-581.	0.3	19
270	Limited miR-17-92 overexpression drives hematologic malignancies. Leukemia Research, 2015, 39, 335-341.	0.4	19

#	Article	IF	CITATIONS
271	MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway. Cancer Letters, 2022, 525, 46-54.	3.2	19
272	Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas. Cancer Genetics and Cytogenetics, 2001, 125, 131-138.	1.0	18
273	Molecular evidence of SARS-CoV-2 in New York before the first pandemic wave. Nature Communications, 2021, 12, 3463.	5.8	18
274	Differential Expression of DNA Nonhomologous End-Joining Proteins Ku70 and Ku80 in Melanoma Progression. Modern Pathology, 2002, 15, 426-433.	2.9	17
275	Comparison of models to predict clinical failure after radical prostatectomy. Cancer, 2009, 115, 303-310.	2.0	17
276	Hydrophilic Agarose Macrobead Cultures Select for Outgrowth of Carcinoma Cell Populations That Can Restrict Tumor Growth. Cancer Research, 2011, 71, 725-735.	0.4	17
277	Blood group antigens in normal and neoplastic urothelium. Journal of Cellular Biochemistry, 1992, 50, 50-55.	1.2	16
278	Establishment, characterization and drug sensitivity of four new human soft tissue sarcoma cell lines., 1996, 68, 514-519.		16
279	Comparison of Gene Expression Profiles in Laser-Microdissected, Nonembedded, and OCT-Embedded Tumor Samples by Oligonucleotide Microarray Analysis. Clinical Chemistry, 2003, 49, 2096-2100.	1.5	16
280	Analysis of adenomatous polyposis coli gene expression, APC locus-microsatellite instability and APC promoter methylation in the progression of melanocytic tumours. Modern Pathology, 2004, 17, 1539-1544.	2.9	16
281	CpG ODN, Toll Like Receptor (TLR)-9 Agonist, Inhibits Metastatic Colon Adenocarcinoma in a Murine Hepatic Tumor Model. Journal of Surgical Research, 2012, 174, 284-290.	0.8	16
282	PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation. Clinical and Translational Oncology, 2012, 14, 197-206.	1.2	16
283	Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN. Methods, 2015, 77-78, 25-30.	1.9	16
284	Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis. Journal of Clinical Investigation, 2018, 129, 215-222.	3.9	16
285	The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization. MSphere, 2022, 7, .	1.3	16
286	Cell-surface antigens of human lung tumors detected by mouse monoclonal antibodies: Definition of blood-group- and non-blood-group-related antigenic systems. International Journal of Cancer, 1990, 46, 1007-1013.	2.3	15
287	Histone Deacetylase Inhibitors: Assays to Assess Effectiveness In Vitro and In Vivo. Methods in Enzymology, 2003, 376, 199-205.	0.4	15
288	Alternate PAX3 and PAX7 C-terminal isoforms in myogenic differentiation and sarcomagenesis. Clinical and Translational Oncology, 2011, 13, 194-203.	1.2	15

#	Article	IF	CITATIONS
289	Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma. Journal of the American Academy of Dermatology, 2014, 70, 1036-1044.e3.	0.6	15
290	Expression of blood group antigens in bladder cancer: Current concepts. Journal of Surgical Oncology, 1992, 8, 308-315.	1.4	14
291	Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer. World Journal of Urology, 1997, 15, 112-119.	1.2	14
292	Molecular Profiling of Coronavirus Disease 2019 (COVID-19) Autopsies Uncovers Novel Disease Mechanisms. American Journal of Pathology, 2021, 191, 2064-2071.	1.9	14
293	Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study. Oncology Reports, 2006, 16, 807-10.	1.2	14
294	Immunohistochemical localization of la nuclear antigen in brain. Journal of Neuroimmunology, 1985, 9, 307-319.	1.1	13
295	Association between cadmium and androgen receptor protein expression differs in prostate tumors of African American and European American men. Journal of Trace Elements in Medicine and Biology, 2018, 48, 233-238.	1.5	13
296	Cytokeratin positivity in paraffin-embedded malignant melanomas: comparative study of KL1, A4 and Lu5 antibodies. Anticancer Research, 2004, 24, 3203-7.	0.5	13
297	Applications of Molecular Diagnostics: Solid Tumor Genetics Can Determine Clinical Treatment Protocols. Modern Pathology, 2001, 14, 254-257.	2.9	12
298	A BAC-Based Transgenic Mouse Specifically Expresses an Inducible Cre in the Urothelium. PLoS ONE, 2012, 7, e35243.	1.1	12
299	A Novel Logistic Model Based on Clinicopathological Features Predicts Microsatellite Instability in Colorectal Carcinomas. Diagnostic Molecular Pathology, 2005, 14, 213-223.	2.1	11
300	Comparative study of p63 and p53 expression in tissue microarrays of malignant melanomas. International Journal of Molecular Medicine, 2002, 10, 707-11.	1.8	11
301	Altered expression and new mutations in DNA mismatch repair genes MLH1 and MSH2 in melanoma brain metastases. Anticancer Research, 2004, 24, 981-6.	0.5	11
302	Analysis of DNA mismatch repair gene expression and mutations in thyroid tumours. Anticancer Research, 2006, 26, 2107-12.	0.5	11
303	H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases. Journal of Pediatric Urology, 2016, 12, 91.e1-91.e7.	0.6	10
304	Myocardial Amyloid Quantification with Look-Locker Magnetic Resonance Sequence in Cardiac Amyloidosis. Diagnostic Accuracy in Clinical Practice and Histological Validation. Journal of Cardiac Failure, 2018, 24, 78-86.	0.7	10
305	Molecular tracing of prostate cancer lethality. Oncogene, 2020, 39, 7225-7238.	2.6	10
306	Altered expression of DNA double-strand repair genes Ku70 and Ku80 in carcinomas of the oral cavity. Anticancer Research, 2006, 26, 2101-5.	0.5	10

#	Article	IF	Citations
307	Targeting sarcoma tumor-initiating cells through differentiation therapy. Stem Cell Research, 2017, 21, 117-123.	0.3	9
308	Protein Profiling of Bladder Urothelial Cell Carcinoma. PLoS ONE, 2016, 11, e0161922.	1.1	9
309	Robust clinical detection of SARSâ€CoVâ€2 variants by RTâ€PCR/MALDIâ€TOF multitarget approach. Journal of Medical Virology, 2022, 94, 1606-1616.	2.5	9
310	Biological Study of R24 Mouse Monoclonal Antibody in Patients Undergoing Thoracotomy for Pulmonary Metastases from Soft Tissue Sarcoma. Cancer Investigation, 1994, 12, 20-25.	0.6	8
311	Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes. Molecular Diagnosis and Therapy, 2017, 21, 115-123.	1.6	8
312	Immunopathologic Assessment of PTEN Expression. Methods in Molecular Biology, 2016, 1388, 23-37.	0.4	8
313	The HOX11/TLX1 Transcription Factor Oncogene Induces Chromosomal Aneuploidy in T-ALL Blood, 2009, 114, 142-142.	0.6	8
314	Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies. Heliyon, 2021, 7, e08444.	1.4	8
315	Antemortem detection of Parkinson's disease pathology in peripheral biopsies using artificial intelligence. Acta Neuropathologica Communications, 2022, 10, 21.	2.4	8
316	Cell surface differentiation antigens of normal urothelium and bladder tumors. Journal of Surgical Oncology, 1992, 8, 293-299.	1.4	7
317	Bladder cancer: advances in biology and treatment. Critical Reviews in Oncology/Hematology, 1994, 16, 33-70.	2.0	7
318	Genomic analysis in active surveillance. Current Opinion in Urology, 2014, 24, 303-310.	0.9	7
319	Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel. Journal of Visualized Experiments, 2017, , .	0.2	7
320	The human leukocyte antigen as a candidate tumor suppressor. Cancer Cell, 2021, 39, 586-589.	7.7	7
321	Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 301.e17-301.e28.	0.8	7
322	Preselection of Patients with High TAG-72 Antigen Expression Leads to Targeting of 94% of Known Metastatic Tumor Sites with Monoclonal Antibody I-131-CC49. Cancer Investigation, 1994, 12, 551-558.	0.6	6
323	Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10â€year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery. BJU International, 2012, 109, 40-45.	1.3	6
324	Prognostic significance of DNA damage repair (DDR) mutations in patients with urothelial carcinoma (UC) and associations with tumor infiltrating lymphocytes (TILs) Journal of Clinical Oncology, 2016, 34, 4538-4538.	0.8	6

#	Article	IF	CITATIONS
325	Decreased expression of Ku70/Ku80 proteins in malignant melanomas of the oral cavity. Anticancer Research, 2002, 22, 193-6.	0.5	6
326	Cytokeratin expression correlates with aneuploidy in cytological specimens of melanoma metastases. Anticancer Research, 2005, 25, 2789-92.	0.5	6
327	Food for thought: Eating before saliva collection and interference with SARSâ€CoVâ€2 detection. Journal of Medical Virology, 2022, 94, 2471-2478.	2.5	6
328	Hotspots for SARSâ€CoVâ€2 Omicron variant spread: Lessons from New York City. Journal of Medical Virology, 2022, 94, 2911-2914.	2.5	6
329	A Novel Multiplexing, Polymerase Chain Reaction-Based Assay for the Analysis of Chromosome 18q Status in Colorectal Cancer. Journal of Molecular Diagnostics, 2005, 7, 478-485.	1.2	5
330	A systemsâ€based modelling approach using transurethral resection of the prostate (TURP) specimens yielded incremental prognostic significance to Gleason when predicting longâ€term outcome in men with localized prostate cancer. BJU International, 2012, 109, 207-213.	1.3	5
331	Association of SARS-CoV-2 viral load at admission with in-hospital acute kidney injury: A retrospective cohort study. PLoS ONE, 2021, 16, e0247366.	1.1	5
332	The New York State SARS-CoV-2 Testing Consortium: Regional Communication in Response to the COVID-19 Pandemic. Academic Pathology, 2021, 8, 23742895211006818.	0.7	5
333	An Oncogenic Metabolic Switch Mediates Resistance to NOTCH1 Inhibition in T-ALL. Blood, 2012, 120, 285-285.	0.6	5
334	Relationship of nm23 expression to proliferation and prognosis in malignant melanomas of the oral cavity. In Vivo, 2005, 19, 1093-6.	0.6	5
335	Association between Incidental Pelvic Inflammation and Aggressive Prostate Cancer. Cancers, 2022, 14, 2734.	1.7	5
336	Compound In Vivo Inactivation of Pml and p53 Uncovers a Functional Interaction in Angiosarcoma Suppression. Genes and Cancer, 2012, 3, 599-603.	0.6	4
337	Isolation of Cancer Stem Cells From Human Prostate Cancer Samples. Journal of Visualized Experiments, 2014, , .	0.2	4
338	The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic. Frontiers in Oncology, 2021, 11, 734963.	1.3	4
339	Inhibition of NOTCH1 Signaling Reverses Glucocorticoid Resistance in T-ALL Blood, 2007, 110, 151-151.	0.6	4
340	Perioperative Polyphenon E, a Green Tea Extract, Does Not Affect the Wound Complication Rate in Mice After Sham Laparotomy yet Has an Inhibitory Effect on Wound Healing. Surgical Innovation, 2012, 19, 399-406.	0.4	3
341	Inhibition of NOTCH1 Signaling and Glucocorticoid Therapy in T-ALL. Blood, 2008, 112, 298-298.	0.6	3
342	RT-PCR and Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry Diagnostic Target Performance Reflects Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variant Diversity in New York City. Journal of Molecular Diagnostics, 2022, , .	1.2	3

#	Article	IF	CITATIONS
343	A Case-Series Study of p53 Nuclear Overexpression in Early-Stage Stomach Cancer. Annals of the New York Academy of Sciences, 1995, 768, 269-271.	1.8	2
344	Overcoming tumor heterogeneity in the molecular diagnosis of urological cancers. Expert Review of Molecular Diagnostics, 2014, 14, 1023-1031.	1.5	2
345	Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens., 1997, 73, 50.		2
346	Genotypic and phenotypic characterization of the histoblood group ABO(H) in primary bladder tumors., 1998, 75, 819.		2
347	Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-na $ ilde{A}$ -ve prostate cancer cells. Aging, 2020, 12, 17694-17712.	1.4	2
348	Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment. Blood, 2021, 138, 822-822.	0.6	2
349	Quantitative Analysis of Ku70 and Ku80 mRNA Gene Expression in Melanoma Brain Metastases. Correlation with Immunohistochemistry and Hybridization. Cancer Genomics and Proteomics, 2004, $1$ , $225-230$ .	1.0	2
350	Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts. Journal of Visualized Experiments, 2019, , .	0.2	1
351	Genetic studies and molecular markers of bladder cancer. , 1997, 13, 319.		1
352	Therapeutic Utility of PI3K $\hat{I}^3$ Inhibition in Leukemogenesis and Tumor Cell Survival. Blood, 2012, 120, 1492-1492.	0.6	1
353	Prostate cancer prognosis via integrative and co-localized glandular morphometry and immunofluorescent protein biomarker expression Journal of Clinical Oncology, 2015, 33, 262-262.	0.8	1
354	Alterations of the retinoblastoma and p16 pathway correlate with promoter methylation in malignant fibrous histiocytomas. Anticancer Research, 2006, 26, 3461-5.	0.5	1
355	Personalized approach to prostate cancer prognosis. Archivos Espanoles De Urologia, 2011, 64, 783-91.	0.1	1
356	The 1999 Fred W. Stewart Award. American Journal of Surgical Pathology, 2000, 24, 295.	2.1	0
357	Transformed bone marrow cells generate neoplasms of distinct histogenesis. a murine model of cancer transplantation. Stem Cell Research, 2019, 41, 101637.	0.3	0
358	Screening peripheral biopsies for alphaâ€synuclein pathology using deep machine learning. Alzheimer's and Dementia, 2020, 16, e047358.	0.4	0
359	Critical Role of Dok-1 and Dok-2 in Leukemia Suppression Blood, 2004, 104, 2951-2951.	0.6	0
360	P1-181: Clinical significance of the AKT pathway in small cell lung cancer and other neuroendocrine tumors. Journal of Thoracic Oncology, 2007, 2, S809.	0.5	0

#	Article	IF	CITATIONS
361	BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia. Blood, 2010, 116, 471-471.	0.6	o
362	A quantitative image analysis model of prostate biopsies for predicting clinical risk in men enrolled in an active surveillance program Journal of Clinical Oncology, 2014, 32, 111-111.	0.8	0
363	A quantitative image analysis model of prostate biopsies for predicting clinical risk in men enrolled in an active surveillance program Journal of Clinical Oncology, 2014, 32, e16002-e16002.	0.8	O
364	ÂÂÂÂÂÂN-Me, a Long Range T-Cell Specific Oncogenic Enhancer in T-ALL. Blood, 2014, 124, 487-487.	0.6	0
365	Characterization of molecular features of pediatric urothelial bladder carcinomas Journal of Clinical Oncology, 2015, 33, 345-345.	0.8	O
366	Incorporation of advanced image analysis in novel post-prostatectomy systems pathology models as an approach to replace the clinical Gleason and provide robust risk stratification Journal of Clinical Oncology, 2015, 33, e16134-e16134.	0.8	0
367	Function of microRNA activity by ActMiR in bladder cancer Journal of Clinical Oncology, 2016, 34, 4531-4531.	0.8	O
368	Prognostic significance of PIK3CA mutation in patients with muscle-invasive urothelial carcinoma (UC) Journal of Clinical Oncology, 2016, 34, e16002-e16002.	0.8	0
369	Creating surveillance data infrastructure using laboratory analytics: Leveraging visiun and epic systems to support COVID-19 pandemic response. Journal of Pathology Informatics, 2022, 13, 100164.	0.8	O
370	Proposal of a new grading system for malignant fibrous histiocytomas. Anticancer Research, 2005, 25, 4293-8.	0.5	0
371	Analysis of the p53-hMDM2-p21 (WAF1/CIP1) Cell Cycle Regulation Pathway in Malignant Fibrous Histiocytomas. Cancer Genomics and Proteomics, 2004, 1, 419-426.	1.0	O